MA40783A - Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population - Google Patents

Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population

Info

Publication number: MA40783A
Authority: MA; Morocco
Prior art keywords: vaccines containing; hiv vaccines; population episensus; episensus antigens; antigens
Prior art date: 2014-10-03

Application number

MA040783A

Other languages

English (en)

Inventor

Eric Bruening

Klaus Frueh

Bette T M Korber

Emily Marshall

Louis Picker

James Theiler

Original Assignee

Los Alamos Nat Security Llc

Univ Oregon Health & Science

Vir Biotechnology Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-10-03

Filing date

2015-10-04

Publication date

2017-08-08

2015-10-04 Application filed by Los Alamos Nat Security Llc, Univ Oregon Health & Science, Vir Biotechnology Inc filed Critical Los Alamos Nat Security Llc

2017-08-08 Publication of MA40783A publication Critical patent/MA40783A/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/867—Retroviral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
- C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
General Engineering & Computer Science (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Oncology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Plant Pathology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

MA040783A 2014-10-03 2015-10-04 Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population MA40783A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201462059497P	2014-10-03	2014-10-03
US201462059506P	2014-10-03	2014-10-03

Publications (1)

Publication Number	Publication Date
MA40783A true MA40783A (fr)	2017-08-08

Family

ID=55631703

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA040783A MA40783A (fr)	2014-10-03	2015-10-04	Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population

Country Status (16)

Country	Link
US (3)	US10894078B2 (fr)
EP (1)	EP3200878B1 (fr)
JP (3)	JP2017531693A (fr)
KR (1)	KR102633096B1 (fr)
CN (1)	CN108064181A (fr)
AU (2)	AU2015327797A1 (fr)
CA (1)	CA2963573C (fr)
EA (1)	EA201790680A1 (fr)
HK (1)	HK1254806A1 (fr)
IL (1)	IL251469B2 (fr)
MA (1)	MA40783A (fr)
MX (3)	MX391149B (fr)
SG (1)	SG11201702729YA (fr)
UA (1)	UA126890C2 (fr)
WO (1)	WO2016054654A1 (fr)
ZA (1)	ZA202206809B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MA40783A (fr)	2014-10-03	2017-08-08	Los Alamos Nat Security Llc	Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
US11980663B2 (en)	2015-07-08	2024-05-14	American Gene Technologies International Inc.	HIV pre-immunization and immunotherapy
US10888613B2 (en)	2016-02-08	2021-01-12	American Gene Technologies International Inc.	Method of producing cells resistant to HIV infection
IL284348B2 (en) *	2016-07-08	2025-06-01	American Gene Tech Int Inc	Hiv pre-immunization and immunotherapy
WO2020243485A1 (fr) *	2019-05-29	2020-12-03	Massachusetts Institute Of Technology	Compositions immunogènes spécifiques du vih-1 et méthodes d'utilisation
JP7454645B2 (ja)	2019-07-16	2024-03-22	ギリアードサイエンシーズ，インコーポレイテッド	Ｈｉｖワクチン並びにその作製方法及び使用方法
CN114729010B (zh)	2019-08-29	2025-02-28	维尔生物科技有限公司	乙型肝炎病毒疫苗
EP4277652A1 (fr) *	2021-01-14	2023-11-22	Gilead Sciences, Inc.	Vaccins contre le vih et méthodes d'utilisation
AU2022339765A1 (en)	2021-08-31	2024-01-25	Vir Biotechnology, Inc.	Recombinant hcmv vectors and uses thereof
TW202436326A (zh) *	2023-02-13	2024-09-16	長怡王	包含hiv th/ctl 抗原決定位胜肽的疫苗用於預防及治療hiv感染及aids患者

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI116851B (fi) *	2001-05-03	2006-03-15	Fit Biotech Oyj Plc	Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
WO2003025003A2 (fr)	2001-09-20	2003-03-27	Glaxo Group Limited	Vaccins
AUPR842501A0 (en) *	2001-10-23	2001-11-15	Epipop Pty Ltd	A method for identification and development of therapeutic agents
US20030190308A1 (en) *	2002-03-19	2003-10-09	Braun Ralph P.	Adjuvant
GB0225788D0 (en) *	2002-11-05	2002-12-11	Glaxo Group Ltd	Vaccine
WO2005012502A2 (fr) *	2003-03-28	2005-02-10	Idm Pharma, Inc.	Procedes d'identification de variants optimaux d'epitopes peptidiques
BRPI0414443A (pt) *	2003-09-17	2006-11-21	Univ Duke	imunógenos consensuais/ancestrais
AU2011203095A1 (en)	2003-09-17	2011-07-21	Duke University	Consensus/Ancestral Immunogens
CN1889963A (zh)	2003-10-10	2007-01-03	宝德杰克特疫苗有限公司	方法
WO2006031264A2 (fr)	2004-05-25	2006-03-23	Oregon Health And Science University	Vaccination du virus de l'immunodeficience simienne (siv) et du virus de l'immunodeficience humaine (vih) utilisant des vecteurs de vaccin a base de rhcmv et hcmv
WO2007024941A2 (fr) *	2005-08-23	2007-03-01	The Regents Of The University Of California	Vaccin polyvalent
MX2009001099A (es) *	2006-07-28	2009-02-10	Univ Pennsylvania	Vacunas mejoradas y metodos para el uso de las mismas.
US20110123485A1 (en)	2007-03-27	2011-05-26	President And Fellows Of Harvard College	Viral vectors for delivering vaccines for hiv and other infectious diseases
CA2681579A1 (fr)	2007-03-30	2008-10-09	Merck & Co., Inc.	Sequences d'antigenes largement representatifs et leur procede de selection
AP3719A (en) *	2008-11-18	2016-06-30	Beth Israel Hospital	Antiviral vaccines with improved cellular immunogenicity
US20120135032A1 (en) *	2009-10-08	2012-05-31	Bavarian Nordic A/S	Generation of a broad t-cell response in humans against hiv
EP2550362B1 (fr)	2010-03-25	2017-01-04	Oregon Health&Science University	Glycoprotéines du cmv et vecteurs recombinés
EP2569436B8 (fr)	2010-05-14	2019-10-30	Oregon Health & Science University	Vecteurs recombinants du hcmv et du rhcmv, et leurs utilisations
US8557787B2 (en) *	2011-05-13	2013-10-15	The Board Of Trustees Of The Leland Stanford Junior University	Diagnostic, prognostic and therapeutic uses of long non-coding RNAs for cancer and regenerative medicine
RS57397B8 (sr)	2011-06-10	2020-01-31	Univ Oregon Health & Science	Cmv glikoproteini i rekombinantni vektori
EP2620446A1 (fr)	2012-01-27	2013-07-31	Laboratorios Del Dr. Esteve, S.A.	Immunogènes pour la vaccination contre le VIH
ES2718899T3 (es)	2012-03-02	2019-07-05	Us Gov Health & Human Services	Método para modificar la jerarquía de inmunodominio de gag del VIH mediante una vacuna de ADN que expresa regiones conservadas
EP2983686B1 (fr) *	2013-01-07	2024-05-29	Beth Israel Deaconess Medical Center, Inc.	Vaccins de trimère d'enveloppe (env) de virus d'immunodéficience humaine (vih) stabilisés et procédés d'utilisation de ceux-ci
EP3473723A1 (fr)	2013-03-05	2019-04-24	Oregon Health & Science University	Vecteurs de cytomégalovirus permettant de contrôler le ciblage des cellules t
US9750801B2 (en)	2014-02-28	2017-09-05	Janssen Vaccines & Prevention B.V.	Replicating recombinant adenovirus vectors, compositions, and methods of use thereof
NZ728208A (en)	2014-07-16	2018-07-27	Univ Oregon Health & Science	Human cytomegalovirus comprising exogenous antigens
HUE053585T2 (hu)	2014-09-26	2021-07-28	Beth Israel Deaconess Medical Ct Inc	Eljárások és készítmények humán immundeficiencia vírus fertõzés elleni védõ immunválasz indukálására
MA40783A (fr)	2014-10-03	2017-08-08	Los Alamos Nat Security Llc	Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
MA47522B1 (fr)	2015-12-15	2021-11-30	Janssen Vaccines & Prevention Bv	Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation

2015
- 2015-10-04 MA MA040783A patent/MA40783A/fr unknown
- 2015-10-05 CA CA2963573A patent/CA2963573C/fr active Active
- 2015-10-05 SG SG11201702729YA patent/SG11201702729YA/en unknown
- 2015-10-05 UA UAA201704021A patent/UA126890C2/uk unknown
- 2015-10-05 WO PCT/US2015/054067 patent/WO2016054654A1/fr not_active Ceased
- 2015-10-05 MX MX2017004275A patent/MX391149B/es unknown
- 2015-10-05 AU AU2015327797A patent/AU2015327797A1/en not_active Abandoned
- 2015-10-05 CN CN201580063643.3A patent/CN108064181A/zh active Pending
- 2015-10-05 US US15/516,491 patent/US10894078B2/en active Active
- 2015-10-05 HK HK18113892.2A patent/HK1254806A1/zh unknown
- 2015-10-05 EA EA201790680A patent/EA201790680A1/ru unknown
- 2015-10-05 IL IL251469A patent/IL251469B2/en unknown
- 2015-10-05 JP JP2017538177A patent/JP2017531693A/ja active Pending
- 2015-10-05 EP EP15847978.2A patent/EP3200878B1/fr active Active
- 2015-10-05 KR KR1020177012171A patent/KR102633096B1/ko active Active
2017
- 2017-03-31 MX MX2022003664A patent/MX2022003664A/es unknown
- 2017-03-31 MX MX2022003663A patent/MX2022003663A/es unknown
2020
- 2020-08-31 US US17/008,335 patent/US11554168B2/en active Active
- 2020-08-31 US US17/008,289 patent/US11628215B2/en active Active
- 2020-10-09 JP JP2020170852A patent/JP7212020B2/ja active Active
2021
- 2021-08-19 AU AU2021218141A patent/AU2021218141B2/en active Active
2022
- 2022-06-20 ZA ZA2022/06809A patent/ZA202206809B/en unknown
2023
- 2023-01-12 JP JP2023003194A patent/JP7441340B2/ja active Active

Also Published As

Publication number	Publication date
JP7441340B2 (ja)	2024-03-06
ZA202206809B (en)	2023-11-29
EP3200878B1 (fr)	2025-06-04
US11554168B2 (en)	2023-01-17
MX391149B (es)	2025-03-21
US20210046175A1 (en)	2021-02-18
IL251469A0 (en)	2017-05-29
MX2022003663A (es)	2022-04-25
JP7212020B2 (ja)	2023-01-24
KR102633096B1 (ko)	2024-02-02
NZ731173A (en)	2024-04-26
HK1254806A1 (zh)	2019-07-26
JP2023059272A (ja)	2023-04-26
US10894078B2 (en)	2021-01-19
AU2015327797A1 (en)	2017-05-11
UA126890C2 (uk)	2023-02-22
EP3200878A4 (fr)	2018-05-30
SG11201702729YA (en)	2017-04-27
EP3200878A1 (fr)	2017-08-09
AU2021218141A1 (en)	2021-09-09
AU2021218141B2 (en)	2024-06-06
KR20170122711A (ko)	2017-11-06
CA2963573C (fr)	2024-02-06
EA201790680A1 (ru)	2017-11-30
IL251469B1 (en)	2023-01-01
CA2963573A1 (fr)	2016-04-07
WO2016054654A1 (fr)	2016-04-07
US20170319679A1 (en)	2017-11-09
IL251469B2 (en)	2023-05-01
JP2017531693A (ja)	2017-10-26
MX2017004275A (es)	2018-01-17
US11628215B2 (en)	2023-04-18
CN108064181A (zh)	2018-05-22
MX2022003664A (es)	2022-04-25
US20210046174A1 (en)	2021-02-18
BR112017006865A2 (pt)	2017-12-12
JP2021035946A (ja)	2021-03-04

Publication	Publication Date	Title
MA40783A (fr)	2017-08-08	Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
EP3364949A4 (fr)	2019-07-31	Vaccins anticancéreux
DK3134131T3 (en)	2022-02-07	Nucleic acid vaccines
EP3413926A4 (fr)	2019-10-09	Vaccination et immunothérapie contre le vih
IL263624B (en)	2022-04-01	HIV vaccine formulation
IL268570B (en)	2021-10-31	Oligonucleotide compositions and methods of making the same
ZA201608327B (en)	2022-08-31	Curcumin-peptide conjugates and formulations thereof
IL266237A (en)	2019-06-30	Tolerogenic DNA composition
EP3528843A4 (fr)	2020-06-03	Vaccins anti-opioïdes
GB201616904D0 (en)	2016-11-16	Vaccine
HUE055700T2 (hu)	2021-12-28	Szülés utáni depresszió elleni módszerek és készítmények
GB201615427D0 (en)	2016-10-26	Francisella glycoconjugate vaccines
PT3534936T (pt)	2020-11-19	Vacina de adn tolerogénica
GB201614387D0 (en)	2016-10-05	Improved vaccines
GB201408819D0 (en)	2014-07-02	Antigen immunogenicity characteristion assay
HK1235003A1 (zh)	2018-03-02	核酸疫苗